Donation

Primary Results of the Aquila Study
ASH
February 24
Daratumumab vs Active Monitoring in High-Risk Smoldering Multiple Myeloma: Aquila Study Results
DREAMM-7: BVd vs DVd in R/R Multiple Myeloma
ASH
January 14
DREAMM-7: BVd vs DVd in Relapsed Refractory Multiple Myeloma - Phase 3 Survival & Efficacy Update
DREAMM7 Belamaf BVd versus DVd
ASCO/EHA
July 12
DREAMM-7: Belamaf+BVd vs DVd in RRMM, subgroup analyses of phase 3 trial comparing regimens after relapse
Improved Depth of Response and MRD Negativity with DARA + VRd in Transplant-Eligible NDMM: PERSEUS Trial Results
ASCO/EHA
June 10
Improved Depth of Response and MRD Negativity with DARA + VRd in Transplant-Eligible NDMM: PERSEUS Trial Results
Comparison of Time to Next Treatment or Death between Front-Line Daratumumab, Lenalidomide, and Dexamethasone (DRd) and Bortezomib, Lenalidomide, and Dexamethasone (VRd) in Transplant Ineligible Patients with Multiple Myeloma
ASH
January 11
Comparison of Time to Next Treatment or Death between Front-Line Daratumumab, Lenalidomide, and Dexamethasone (DRd) and Bortezomib, Lenalidomide, and Dexamethasone (VRd) in Transplant Ineligible Patients with Multiple Myeloma
Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Vrd Alone in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Eligible for Autologous Stem Cell Transplantation (ASCT): Primary Results of the Perseus Trial
ASH
January 8
Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Vrd Alone in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Eligible for ASCT: Primary Results of the Perseus Trial
nurse giving patient injection
Week in Review
December 21
Preparing for and Looking Forward to 2024
EHA23 Dr. Luciano Costa presents the final analysis of the MASTER trial
ASCO/EHA
July 1
Quadruplet Induction Therapy, ASCT and MRD-modulated Consolidation and Treatment Cessation in Newly Diagnosed Multiple Myeloma
PFS Boca Raton
Week in Review
March 23
Patient & Family Seminar in Boca Raton: A Successful In-Person Reunion
Dr. Grosicki abstract on MagnetisMM-5
ASH
February 10
Elranatamab in Combination with Daratumumab for Patients with Relapsed Refractory Multiple Myeloma: Phase 3 MagnetisMM-5
Phase 2 IFM 2018-04 Study Results Presented at ASCO 2022
ASCO/EHA
June 29
Dara-KRd as induction therapy in high-risk, transplant-eligible patients with newly diagnosed myeloma: Results of the phase 2 study IFM 2018-04
Post Hoc Analysis of Sustained MRD Negativity
ASCO/EHA
June 28
Analysis of sustained MRD negativity (GRIFFIN Trial) using daratumumab plus RVD in transplant-eligible newly diagnosed multiple myeloma
Subscribe to daratumumab

Give Where Most Needed

Learn More